Chondroitin Sulfate has shown to be effective compared to placebo for pain relief and improvement of functional disability in patients with osteoarthritis.
The clinical efficacy of Chondroitin Sulfate has been widely demonstrated and the conclusion from this comprehensive review of studies published to date was that Chondroitin Sulfate has a positive effect treating the symptoms and the progression of osteoarthritis.
To date, the first meta-analysis study was performed in 2000 in which 7 trials on 372 patients taking CS were considered. Several other meta-analyses of clinical trials have been published since that first report. CS, alone or in combination with other agents, was found able to reduce joint pain and to slow down the rate of reduction of joint space in patients suffering of OA.
Chondroitin Sulfate is currently recommended as the baseline treatment for osteoarthritis by the most important guidelines in Rheumatology: in the EULAR (European League Against Rheumatism) Guidelines chondroitin sulfate is recommended as a SYSADOA (Symptomatic Slow Acting Drug for Osteoarthritis).
ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis ) Guidelines recommend chondroitin as background treatment for osteoarthritis. It is recommended as chronic prescription option in the first step of a proposed algorithm for the treatment of knee osteoarthritis.